NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Genomic Medicine > New test offers breakthrough in IVF success rates

New test offers breakthrough in IVF success rates

20 October 2015 · Listed under Genomic Medicine

One of the most important factors influencing the success of IVF treatment is the health of the embryo selected for transfer to the womb.

Approximately 85 per cent of all embryos transferred do not ultimately go on to produce a baby. In recent years the importance of counting chromosomes in the cells of embryos was discovered.

Yet even when embryos with the correct number of chromosomes are transferred, about one-third still fail to implant for reasons yet unknown.

However research teams at Reprogenetics and the University of Oxford have now discovered a new factor that influences the success of IVF – the level of an embryo’s Mitochondrial DNA.

Between a quarter and a third of embryos have abnormal levels of mitochondrial DNA which means they will never implant.

Microscopic bodies, hundreds or thousands of Mitochondria can be found within each of our cells. They are responsible for producing the energy needed by cells, essential for life. Each mitochondrion contains a small quantity of DNA.

Dr Elpida Fragouli, who led the research at Reprogenetics, said: “Based on our findings we have devised a test whereby a small number of cells, carefully removed from an embryo, can be measured for the amount of mitochondrial DNA present. This will help guide doctors to the IVF embryos with the greatest chance of producing a viable pregnancy.”

Prof Dagan Wells, who is funded by the NIHR Oxford Biomedical Research Centre, said: “Currently, only about one IVF treatment in every three succeeds in helping a couple to have a baby.

“Anything that reduces the number of unsuccessful embryo transfers that patients have to endure will certainly be welcome. This important discovery indicates that mitochondria represent an important piece in the complex jigsaw puzzle that is infertility.”

The research also revealed that the levels of mitochondrial DNA in embryos tend to increase as women age, implicating mitochondria with reproductive ageing.

Trials of the new technology for mitochondrial DNA assessment, which has been christened MitoGrade, are already underway in the United States, while Reprogenetics is in the processes of applying to the British IVF regulator, the Human Fertilisation and Embryology Authority (HFEA), for permission to offer this test in the UK.

Initial data from 100 American patients suggests that the chance of choosing a viable embryo for transfer is likely to be boosted by 10 per cent if MitoGrade results are taken into consideration.

← 100,000 Genomes Project video online
Faster TB results from BRC-backed research →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre